AF
ADVM

Amalgamated Financial’s Adverum Biotechnologies ADVM Stock Holding History

Amalgamated Financial’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$14K Buy
+1,046
New +$15.3K ﹤0.01% 2826

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Amalgamated Financial's ADVM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Adverum Biotechnologies (ADVM) in Q1 2022: 1,046 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #2826 among its holdings.

92 funds tracked by Wall St. Rank hold ADVM as of Q1 2022.

  • Amalgamated Financial held 1,046 shares of Adverum Biotechnologies worth $14K as of Q1 2022.
  • Adverum Biotechnologies was a new Amalgamated Financial position in Q1 2022.
  • Adverum Biotechnologies made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2826 holding.
  • 92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.